Ryosuke Higuchi

Ryosuke Higuchi

Auto-generated profile, based on publicly available information

Ryosuke Higuchi

Department of Cardiology, Sakakibara Heart Institute

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 December 2022 in JACC: Asia
Verified
Journal Article
Open access
TTTaiyo Tezuka
Taiyo Tezuka
RHRyosuke Higuchi
Ryosuke Higuchi
KHKenichi Hagiya
Kenichi Hagiya
MSMike Saji
Mike Saji
ITItaru Takamisawa
Itaru Takamisawa
MTMorimasa Takayama
Morimasa Takayama
Obesity is a major risk factor for cardiovascular disease; however, a paradoxical effect of obesity has been reported in patients with heart failure or myocardial infarction. Although several studies have suggested the same obesity paradox in patients undergoing transcatheter aortic valve replacement (TAVR), they included a limited number of underweight patients. This study aimed to clarify the effect of being underweight on TAVR outcomes. We retrospectively analyzed 1,693 consecutive patients undergoing TAVR between 2010 and 2020. The patients were categorized according to body mass index: underweight (25 kg/m2; n = 396). We compared midterm outcomes after TAVR among the 3 groups; all clinical events were in accordance with the Valve Academic Research Consortium-2 criteria. Underweight patients were more likely to be women and have severe heart failure symptoms, peripheral artery disease, anemia, hypoalbuminemia, and pulmonary dysfunction. They also had lower ejection fractions, smaller aortic valve areas, and higher surgical risk scores. Device failure, life-threatening bleeding, major vascular complications, and 30-day mortality occurred more frequently in underweight patients. The midterm survival rate of the underweight group was inferior to those of the other 2 groups (P < 0.0001; average follow-up, 717 days). In the multivariate analysis, underweight was associated with noncardiovascular mortality (HR: 1.78; 95% CI: 1.16-2.75) but not cardiovascular mortality (HR: 1.28; 95% CI: 0.58-1.88) after TAVR. Underweight patients had a worse midterm prognosis, demonstrating the obesity paradox in this TAVR population. (Outcomes of transcatheter aortic valve implantation in Japanese patients with aortic stenosis: multi-center registry; UMIN000031133).

2 May 2018 in Heart and Vessels
Verified
Journal Article
Closed access
PDF file
RHRyosuke Higuchi
Ryosuke Higuchi
TTTetsuya Tobaru
Tetsuya Tobaru
KHKenichi Hagiya
Kenichi Hagiya
MSMike Saji
Mike Saji
ITItaru Takamisawa
Itaru Takamisawa
MIMitsuaki Isobe
Mitsuaki Isobe

25 July 2019 in Circulation Journal
Verified
Journal Article
Open access
PDF file
MSMike Saji
Mike Saji
TTTetsuya Tobaru
Tetsuya Tobaru
RHRyosuke Higuchi
Ryosuke Higuchi
KMKeitaro Mahara
Keitaro Mahara
ITItaru Takamisawa
Itaru Takamisawa
MIMitsuaki Isobe
Mitsuaki Isobe
Background:The purpose of this study was to investigate if the transcatheter aortic valve replacement (TAVR) risk score can independently predict outcomes following TAVR, and to evaluate its predictive performance.Methods and Results:This retrospective multicenter study comprised 682 patients with severe aortic stenosis who underwent TAVR. The primary endpoint was all-cause death following TAVR. The clinical model was established using variables identified as independent predictors in the multivariate analysis. Incremental values were assessed after adding atrial fibrillation, body mass index (BMI), and serum albumin to the TAVR risk score in receiver-operating characteristic analysis. The median TAVR risk score was 2.1% with a mean follow-up of 505 days. On Kaplan-Meier analysis, a TAVR risk score >4% had lowest survival rate, whereas TAVR risk score ≤2% had the highest survival rate at 3 years (log-rank P<0.001). The multivariate Cox regression analysis found the TAVR risk score was independently associated with all-cause death, and demonstrated moderate predictive performance for predicting all-cause death at 3 years. However, if each independent predictor is added to the model, it significantly increased discriminatory performance, particularly with BMI and serum albumin level.Conclusions:We demonstrated that the TAVR risk score could independently predict mid-term death following TAVR, and had greater predictive performance for predicting all-cause death at 3 years with BMI and serum albumin level.

2 May 2022 in IJC Heart & Vasculature
Verified
Journal Article
Open access
YKYoshimasa Kojima
Yoshimasa Kojima
RHRyosuke Higuchi
Ryosuke Higuchi
KHKenichi Hagiya
Kenichi Hagiya
MSMike Saji
Mike Saji
ITItaru Takamisawa
Itaru Takamisawa
MIMitsuaki Isobe
Mitsuaki Isobe
Malignancy is common in older adults undergoing transcatheter aortic valve implantation (TAVI), and may affect prognosis. The present study aimed to examine whether active cancer affects all-cause mortality rates among patients undergoing TAVI. This retrospective study examined data from 1,114 consecutive patients treated between April 2010 and June 2019. Patients with life expectancy of <1 year due to non-cardiac causes were excluded. Active cancer was defined as cancer under treatment or cured within 1 year, and was recognized in 62 patients (5.6%) with (n = 17) and without (n = 45) metastases. In multivariate analysis, being female (hazard ratio [HR] 0.55, 95% confidence interval [CI] 0.39–0.77, p < 0.001), body mass index (BMI) (HR = 0.92 per 1 kg/m2 increase, 95% CI 0.87–0.97, p = 0.001), New York Heart Association (NYHA) class III/IV (HR = 1.53, 95% CI 1.06–2.20, p = 0.022), atrial fibrillation (HR = 2.40, 95% CI 1.70–3.38, p < 0.001), albumin levels (HR = 0.41 per 1-g/dl, 95% CI 0.30–0.57, p < 0.001), and cancer metastasis (HR = 5.28, 95% CI 1.86–14.9, p = 0.001) were associated with all-cause mortality after TAVI. In patients undergoing TAVI, being female, high BMI, NYHA class III/IV, atrial fibrillation, albumin levels, and cancer metastasis were factors associated with mortality. Meanwhile, active cancer without metastasis was not associated with increased mortality rates. These findings would help clinical decision-making by patients and physicians. Clinical trial registration: UMIN000031133.

1 March 2019 in European Heart Journal - Case Reports
Verified
Journal Article
Open access
PDF file
HFHiroshi Fukunaga
Hiroshi Fukunaga
RHRyosuke Higuchi
Ryosuke Higuchi
KTKohei Tanizaki
Kohei Tanizaki
MIMitsuaki Isobe
Mitsuaki Isobe
Cryoballoon ablation (CBA) has been widely accepted as a treatment of paroxysmal atrial fibrillation (PAF),1 however, serious procedural complications can occur, including oesophageal ulcer, atrio-oesophageal fistula, bronchial injury, and phrenic nerve injury.2

19 August 2023 in IJC Heart & Vasculature
Verified
Journal Article
Open access
KNKota Nishida
Kota Nishida
MSMike Saji
Mike Saji
RHRyosuke Higuchi
Ryosuke Higuchi
ITItaru Takamisawa
Itaru Takamisawa
MNMamoru Nanasato
Mamoru Nanasato
MIMitsuaki Isobe
Mitsuaki Isobe
Information regarding the outcomes of transcatheter aortic valve replacement (TAVR) in men is limited. This study aimed to investigate short- to mid-term outcomes and prognostic predictors in this population. The data of 519 men were analyzed from 1,693 consecutive patients with symptomatic severe aortic stenosis who underwent TAVR at six hospitals between April 2010 and July 2020. The primary endpoint was all-cause mortality at 30 days after TAVR. The mean age and Society of Thoracic Surgeons (STS) score were 83.7 ± 5.9 years and 6.3 ± 4.7%, respectively. Overall, 23.5% of patients consumed alcohol with a frequency of > 1 drinks/week, and 12.1% consumed alcohol with a frequency of > 8 drinks/week, while 66.1% were former smokers and 4.2% were current smokers. Mortality at 30 days was 0.8%. During the median follow-up period of 448 days, the estimated survival rates at 1 year post-TAVR was 90.7 ± 1.4%. In multivariate analysis, the serum albumin level [hazard ratio (HR): 2.20, 95% confidence interval (CI):1.36–3.62, p = 0.001], atrial fibrillation (HR: 1.79, 95% CI: 1.13–2.82, p = 0.012), and STS score (HR: 1.33, 95% CI: 1.06–1.67, p = 0.015) were independently associated with all-cause mortality following TAVR. Adjusted hazard ratios of current smoking, heavy drinking, and presence of cancer were 1.05 (95% CI: 0.36–2.98),1.37 (95% CI: 0.75–2.48), and 1.13 (95% CI: 0.75–2.48), respectively. Our study demonstrated that serum albumin levels, atrial fibrillation, and STS score were independently associated with all-cause mortality following TAVR in men.